HCPCS C9608: Revascularization for Chronic Total Occlusion, Additional Vessel
Commercial payers pay $6249 on average nationally for this procedure.
HCPCS Level II code C9608 describes percutaneous transluminal revascularization of a chronic total occlusion in a coronary artery, branch, or bypass graft when a combination of drug-eluting intracoronary stent, atherectomy, and angioplasty is used; this code is reported for each additional coronary vessel, branch, or bypass graft in addition to the primary procedure. Service type is percutaneous coronary revascularization and the typical site of service is an interventional cardiology catheterization laboratory or hospital cardiac cath suite.
For related coverage guidance, see recent payer policy updates: Cardiac Computed Tomography (CCT)/Coronary Computed Tomographic Angiography (CCTA), Cardiovascular Disease Risk Assessment, Biomarkers for Myocardial Infarction and Chronic Heart Failure.
Customize your policy alerts
Sign up for hcpcs C9608 policy alerts
Get alerted when payer policies referencing C9608 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial rates for C9608 cluster around a BUCA average commercial rate of $6,249.40, positioning that benchmark between several payer-specific distributions. Cigna shows the highest central tendency with a median of $16,622 and a wide upper tail (P90 $34,529), while Aetna and UnitedHealth Group have lower medians of $3,682 and $717 respectively. Blue Cross Blue Shield sits with a modest median of $655.70. These contrasts indicate distinct contracting structures across payers, with BUCA’s mean reflecting an overall commercial midpoint rather than the extremes.
Assessing dispersion (P75 minus P25) highlights variability: Cigna’s IQR is $12,439 (P75 $23,548.60 minus P25 $11,159.10), Aetna’s is $5,693.80, BUCA’s is $5,704.50, UnitedHealth Group’s is $2,705.60, and Blue Cross Blue Shield’s is $3,856.00. Cigna therefore exhibits the widest spread, while UnitedHealth Group is the tightest, signaling more concentrated reimbursement levels for UnitedHealth Group compared with greater variability for Cigna.